{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:16:54Z","timestamp":1791389814361,"version":"4.3.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:00:00Z","timestamp":1757203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04048-z","type":"journal-article","created":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:30:23Z","timestamp":1757255423000},"page":"934-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-4101","authenticated-orcid":false,"given":"Manuel","family":"S\u00e1nchez C\u00e1novas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"L\u00f3pez Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Jos\u00e9","family":"Garc\u00eda Verdejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cacho Lavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Garrido Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Coma Salvans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Quintanar Verduguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Salvador Coloma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fern\u00e1ndez Garay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 David","family":"Cumplido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Isabel","family":"Ferrer P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Carb\u00f3 Bagu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Teigell Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Garc\u00eda L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mart\u00ednez Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.","family":"Mu\u00f1oz Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,7]]},"reference":[{"issue":"1","key":"4048_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13048-023-01094-5","volume":"16","author":"Y Wu","year":"2023","unstructured":"Wu Y, Xu S, Cheng S, Yang J, Wang Y. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. J Ovarian Res. 2023;16(1):6.","journal-title":"J Ovarian Res"},{"issue":"15","key":"4048_CR2","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382\u201392.","journal-title":"N Engl J Med"},{"issue":"9","key":"4048_CR3","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","volume":"119","author":"M Friedlander","year":"2018","unstructured":"Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018;119(9):1075\u201385.","journal-title":"Br J Cancer"},{"issue":"5","key":"4048_CR4","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(5):620\u201331.","journal-title":"Lancet Oncol"},{"issue":"9","key":"4048_CR5","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"Lancet Oncol"},{"issue":"25","key":"4048_CR6","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, P\u00e9rol D, Gonz\u00e1lez-Mart\u00edn A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"issue":"25","key":"4048_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"22","key":"4048_CR8","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"5","key":"4048_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","volume":"21","author":"JA Ledermann","year":"2020","unstructured":"Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(5):710\u201322.","journal-title":"Lancet Oncol"},{"issue":"15","key":"4048_CR10","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","volume":"23","author":"R Kristeleit","year":"2017","unstructured":"Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1\/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23(15):4095\u2013106.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4048_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75\u201387.","journal-title":"Lancet Oncol"},{"issue":"10","key":"4048_CR12","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1055\/a-1816-8347","volume":"122","author":"A Carmona-Bayonas","year":"2022","unstructured":"Carmona-Bayonas A, Verso M, S\u00e1nchez C\u00e1novas M, Rubio P\u00e9rez J, Garc\u00eda de Herreros M, Mart\u00ednez Del Prado P, et al. Do antiangiogenics promote clot instability? Data from the TESEO prospective registry and caravaggio clinical trial. Thromb Haemost. 2022;122(10):1653\u201361. https:\/\/doi.org\/10.1055\/a-1816-8347.","journal-title":"Thromb Haemost"},{"issue":"18","key":"4048_CR13","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.3390\/cancers13184603","volume":"13","author":"M Saerens","year":"2021","unstructured":"Saerens M, De Jaeghere EA, Kanervo H, Vandemaele N, Denys H, Naert E. Risk of thrombo-embolic events in ovarian cancer: does bevacizumab tilt the scale? A systematic review and meta-analysis. Cancers (Basel). 2021;13(18):4603. https:\/\/doi.org\/10.3390\/cancers13184603.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4048_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1160\/TH15-06-0520","volume":"115","author":"P Perez-Segura","year":"2016","unstructured":"Perez-Segura P, Zamorano-Le\u00f3n JJ, Acosta D, Santos-Sancho JM, Modrego J, Cald\u00e9s T, de la Hoya M, et al. BRCA2 gene mutations and coagulation-associated biomarkers. Thromb Haemost. 2016;115(2):415\u201323. https:\/\/doi.org\/10.1160\/TH15-06-0520.","journal-title":"Thromb Haemost"},{"issue":"1","key":"4048_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12094-021-02678-7","volume":"24","author":"AJ Mu\u00f1oz","year":"2022","unstructured":"Mu\u00f1oz AJ, de Toro M, Ortega L, L\u00f3pez C, Guti\u00e9rrez A, Juliao DS, et al. Venous thromboembolism incidence in cancer patients with germline BRCA mutations. Clin Transl Oncol. 2022;24(1):154\u20138. https:\/\/doi.org\/10.1007\/s12094-021-02678-7.","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"4048_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D\u2019Andrea AD. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov. 2015;5(11):1137\u201354. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0714.","journal-title":"Cancer Discov"},{"key":"4048_CR17","doi-asserted-by":"publisher","first-page":"102601","DOI":"10.1016\/j.ctrv.2023.102601","volume":"119","author":"G Castellano","year":"2023","unstructured":"Castellano G, Corti C, Boldrini L, Gervaso L, Criscitiello C, Curigliano G. Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: a systematic review and meta-analysis of phase 3 randomized controlled trials. Cancer Treat Rev. 2023;119:102601. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102601.","journal-title":"Cancer Treat Rev"},{"key":"4048_CR18","doi-asserted-by":"publisher","first-page":"104376","DOI":"10.1016\/j.critrevonc.2024.104376","volume":"198","author":"SC Yazgan","year":"2024","unstructured":"Yazgan SC, Akkus E, Yekeduz E, Urun Y. Thromboembolic risk in prostate cancer patients treated with PARP inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2024;198:104376. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104376.","journal-title":"Crit Rev Oncol Hematol"}],"updated-by":[{"DOI":"10.1007\/s12094-025-04074-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000}}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04048-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04048-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04048-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:19:10Z","timestamp":1771510750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04048-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,7]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4048"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04048-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,7]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct Figures 1 and 2, two paragraphs starting 'Table 3 and Figure 1 presents...' and 'A Kaplan\u2013Meier survival analysis...'.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12094-025-04074-x","URL":"https:\/\/doi.org\/10.1007\/s12094-025-04074-x","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest related to the development of this research project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was submitted to the Ethics Committee of each participating center and obtained the corresponding approval prior to its commencement. The processing, communication, and transfer of all personal data complied with the provisions of Organic Law 15\/1999, dated December 13, 1999, regarding the protection of personal data and of Organic Law 3\/2018, dated December 5, 2018, since it came into force.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}